Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Biglycan enhances gastric cancer invasion by activating FAK signaling pathway.

Hu L, Duan YT, Li JF, Su LP, Yan M, Zhu ZG, Liu BY, Yang QM.

Oncotarget. 2014 Apr 15;5(7):1885-96.

2.

Maternal embryonic leucine zipper kinase enhances gastric cancer progression via the FAK/Paxillin pathway.

Du T, Qu Y, Li J, Li H, Su L, Zhou Q, Yan M, Li C, Zhu Z, Liu B.

Mol Cancer. 2014 May 4;13:100. doi: 10.1186/1476-4598-13-100.

3.

Biglycan enhances the ability of migration and invasion in endometrial cancer.

Sun H, Wang X, Zhang Y, Che X, Liu Z, Zhang L, Qiu C, Lv Q, Jiang J.

Arch Gynecol Obstet. 2016 Feb;293(2):429-38. doi: 10.1007/s00404-015-3844-5. Epub 2015 Aug 15.

PMID:
26275380
4.

Overexpression of LIMK1 promotes tumor growth and metastasis in gastric cancer.

You T, Gao W, Wei J, Jin X, Zhao Z, Wang C, Li Y.

Biomed Pharmacother. 2015 Feb;69:96-101. doi: 10.1016/j.biopha.2014.11.011. Epub 2014 Nov 20.

PMID:
25661344
5.

RABEX-5 is upregulated and plays an oncogenic role in gastric cancer development by activating the VEGF signaling pathway.

Wang S, Lu A, Chen X, Wei L, Ding J.

PLoS One. 2014 Nov 26;9(11):e113891. doi: 10.1371/journal.pone.0113891. eCollection 2014.

6.
7.

Biglycan expression correlates with aggressiveness and poor prognosis of gastric cancer.

Wang B, Li GX, Zhang SG, Wang Q, Wen YG, Tang HM, Zhou CZ, Xing AY, Fan JW, Yan DW, Qiu GQ, Yu ZH, Peng ZH.

Exp Biol Med (Maywood). 2011 Nov;236(11):1247-53. doi: 10.1258/ebm.2011.011124. Epub 2011 Oct 13.

PMID:
21998129
8.

CEACAM6 promotes tumor angiogenesis and vasculogenic mimicry in gastric cancer via FAK signaling.

Zang M, Zhang Y, Zhang B, Hu L, Li J, Fan Z, Wang H, Su L, Zhu Z, Li C, Yan C, Gu Q, Liu B, Yan M.

Biochim Biophys Acta. 2015 May;1852(5):1020-8. doi: 10.1016/j.bbadis.2015.02.005. Epub 2015 Feb 19.

9.

MicroRNA-148a suppresses tumor cell invasion and metastasis by downregulating ROCK1 in gastric cancer.

Zheng B, Liang L, Wang C, Huang S, Cao X, Zha R, Liu L, Jia D, Tian Q, Wu J, Ye Y, Wang Q, Long Z, Zhou Y, Du C, He X, Shi Y.

Clin Cancer Res. 2011 Dec 15;17(24):7574-83. doi: 10.1158/1078-0432.CCR-11-1714. Epub 2011 Oct 12. Erratum in: Clin Cancer Res. 2012 Aug 1;18(15)4216.

10.

IL-1β-induced activation of p38 promotes metastasis in gastric adenocarcinoma via upregulation of AP-1/c-fos, MMP2 and MMP9.

Huang Q, Lan F, Wang X, Yu Y, Ouyang X, Zheng F, Han J, Lin Y, Xie Y, Xie F, Liu W, Yang X, Wang H, Dong L, Wang L, Tan J.

Mol Cancer. 2014 Jan 31;13:18. doi: 10.1186/1476-4598-13-18.

11.

CEACAM6 promotes gastric cancer invasion and metastasis by inducing epithelial-mesenchymal transition via PI3K/AKT signaling pathway.

Zang M, Zhang B, Zhang Y, Li J, Su L, Zhu Z, Gu Q, Liu B, Yan M.

PLoS One. 2014 Nov 14;9(11):e112908. doi: 10.1371/journal.pone.0112908. eCollection 2014.

12.

Tissue transglutaminase-2 promotes gastric cancer progression via the ERK1/2 pathway.

Wang X, Yu Z, Zhou Q, Wu X, Chen X, Li J, Zhu Z, Liu B, Su L.

Oncotarget. 2016 Feb 9;7(6):7066-79. doi: 10.18632/oncotarget.6883.

13.

High expression of biglycan is associated with poor prognosis in patients with esophageal squamous cell carcinoma.

Zhu YH, Yang F, Zhang SS, Zeng TT, Xie X, Guan XY.

Int J Clin Exp Pathol. 2013 Oct 15;6(11):2497-505. eCollection 2013.

14.

Androgen receptor promotes gastric cancer cell migration and invasion via AKT-phosphorylation dependent upregulation of matrix metalloproteinase 9.

Zhang BG, Du T, Zang MD, Chang Q, Fan ZY, Li JF, Yu BQ, Su LP, Li C, Yan C, Gu QL, Zhu ZG, Yan M, Liu B.

Oncotarget. 2014 Nov 15;5(21):10584-95.

15.

Epidermal growth factor-like domain-containing protein 7 (EGFL7) enhances EGF receptor-AKT signaling, epithelial-mesenchymal transition, and metastasis of gastric cancer cells.

Luo BH, Xiong F, Wang JP, Li JH, Zhong M, Liu QL, Luo GQ, Yang XJ, Xiao N, Xie B, Xiao H, Liu RJ, Dong CS, Wang KS, Wen JF.

PLoS One. 2014 Jun 19;9(6):e99922. doi: 10.1371/journal.pone.0099922. eCollection 2014.

16.

Secreted LOXL2 is a novel therapeutic target that promotes gastric cancer metastasis via the Src/FAK pathway.

Peng L, Ran YL, Hu H, Yu L, Liu Q, Zhou Z, Sun YM, Sun LC, Pan J, Sun LX, Zhao P, Yang ZH.

Carcinogenesis. 2009 Oct;30(10):1660-9. doi: 10.1093/carcin/bgp178. Epub 2009 Jul 22.

PMID:
19625348
17.
18.

Knockdown of HMGB1 inhibits growth and invasion of gastric cancer cells through the NF-κB pathway in vitro and in vivo.

Zhang J, Kou YB, Zhu JS, Chen WX, Li S.

Int J Oncol. 2014 Apr;44(4):1268-76. doi: 10.3892/ijo.2014.2285. Epub 2014 Jan 28.

PMID:
24481712
19.

BTG1 expression correlates with pathogenesis, aggressive behaviors and prognosis of gastric cancer: a potential target for gene therapy.

Zheng HC, Li J, Shen DF, Yang XF, Zhao S, Wu YZ, Takano Y, Sun HZ, Su RJ, Luo JS, Gou WF.

Oncotarget. 2015 Aug 14;6(23):19685-705.

20.

Phosphorylation of focal adhesion kinase at Tyr397 in gastric carcinomas and its clinical significance.

Lai IR, Chu PY, Lin HS, Liou JY, Jan YJ, Lee JC, Shen TL.

Am J Pathol. 2010 Oct;177(4):1629-37. doi: 10.2353/ajpath.2010.100172. Epub 2010 Aug 19.

Supplemental Content

Support Center